Cite
MLA Citation
Karl Lewis et al.. “Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib.” European journal of cancer, vol. 116, 2019, pp. 45–55. http://access.bl.uk/ark:/81055/vdc_100086504434.0x000028